Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals

Molecular Carcinogenesis

Volumn 48, Issue 8, 2009, Pages 758-772

  Xu, Haibo ^a   McCann, Mella ^a   Zhang, Zhiyu ^b   Posner, Gary H ^b   Bingham, Victoria ^a   El Tanani, Mohamed ^a   Campbell, Frederick C ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

1 ,25 (OH)2 D3; Analogs; Osteopontin; Vitamin D receptor; catenin

Indexed keywords

BETA CATENIN; FIBRONECTIN; LYMPHOID ENHANCER FACTOR 1; OSTEOPONTIN; T CELL FACTOR PROTEIN; UVOMORULIN; VITAMIN D RECEPTOR; CADHERIN; CALCITRIOL RECEPTOR; CTNNB1 PROTEIN, HUMAN; DRUG DERIVATIVE; LUCIFERASE; VITAMIN D;

ANIMAL CELL; ARTICLE; CELL ADHESION; CELL GROWTH; CELL INVASION; CONTROLLED STUDY; GENETIC TRANSFECTION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; COLORECTAL TUMOR; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHENOTYPE; PROMOTER REGION; SITE DIRECTED MUTAGENESIS; VITAMIN D RESPONSIVE ELEMENT; WESTERN BLOTTING;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CADHERINS; CELL ADHESION; COLORECTAL NEOPLASMS; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; LYMPHOID ENHANCER-BINDING FACTOR 1; MAMMARY NEOPLASMS, EXPERIMENTAL; MUTAGENESIS, SITE-DIRECTED; OSTEOPONTIN; PHENOTYPE; PROMOTER REGIONS, GENETIC; RATS; RECEPTORS, CALCITRIOL; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; VITAMIN D; VITAMIN D RESPONSE ELEMENT;

EID: 68549126202     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20520     Document Type: Article

References (68)

1. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001;154:369-387.
2. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/ Tcf signaling axis: Wnt you like to know? Endocr Rev 2005;26:898-915.
3. Murillo G, Mehta RG. Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alphahydroxyvitamin D5. J Steroid Biochem Mol Biol 2005;97: 129-136. (Pubitemid 41546222)
4. Haussler MR, Haussler CA, Jurutka PW, et al. The vitamin D hormone and its nuclear receptor: Molecular actions and disease states. J Endocrinol 1997;154:S57-S73. (Pubitemid 27380871)
5. Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phospho-protein 1 (SPP-1 or osteopontin) gene expression. Proc Natl Acad Sci USA 1990;87:9995-9999.
6. El-Tanani M, Platt-Higgins A, Rudland PS, Campbell FC. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem 2004; 279:20794-20806.
7. El-Tanani M, Barraclough R, Wilkinson MC, Rudland PS. Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res 2001;61:5619-5629. (Pubitemid 32694949)
8. Chang PL, Cao M, Hicks P. Osteopontin induction is required for tumor promoter-induced transformation of preneo-plastic mouse cells. Carcinogenesis 2003;24:1749-1758. (Pubitemid 37408137)
9. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10:184-190.
10. Tuck AB, Arsenault DM, O'Malley FP, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999;18:4237-4246.
11. Kurisetty VV, Johnston PG, Johnston N, et al. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Oncogene 2008;27:7139-7149.
12. Norman AW, Ishizuka S, Okamura WH. Ligands for the vitamin D endocrine system: Different shapes function as agonists and antagonists for genomic and rapid response receptors or as a ligand for the plasma vitamin D binding protein. J Steroid Biochem Mol Biol 2001;76:49-59. (Pubitemid 32510667)
13. Weyts FA, Dhawan P, Zhang X, et al. Novel Gemini analogs of 1alpha,25-dihydroxyvitamin D(3) with enhanced transcriptional activity. Biochem Pharmacol 2004;67:1327-1336.
14. Liu YY, Nguyen C, Peleg S. Regulation of ligand-induced heterodimerization and coactivator interaction by the activation function-2 domain of the vitamin D receptor. Mol Endocrinol 2000;14:1776-1787.
15. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000;5:173-179. (Pubitemid 30105446)
16. Posner GH, Lee JK, White MC, et al. Antiproliferative hybrid analogs of the hormone 1alpha,25-dihydroxyvitamin D(3): Design, synthesis, and preliminary biological evaluation. J Org Chem 1997;62:3299-3314.
17. Posner GH, Jeon HB, Sarjeant A, et al. Low-calcemic, efficacious, 1alpha,25-dihydroxyvitamin D3 analog QW- 1624F2-2: Calcemic dose-response determination, preclinical genotoxicity testing, and revision of A-ring stereochemistry. Steroids 2004;69:757-762. (Pubitemid 39576719)
18. Posner GH, Lee JK, Wang Q, et al. Noncalcemic, antiproliferative, transcriptionally active, 24-fluorinated hybrid analogues of the hormone 1alpha, 25-dihydroxyvitamin D3. Synthesis and preliminary biological evaluation. J Med Chem 1998;41:3008-3014. (Pubitemid 28359936)
19. Posner GH, Woodard BT, Crawford KR, et al. 2,2-Disubstituted analogues of the natural hormone 1 alpha,25- dihydroxyvitamin D(3): Chemistry and biology. Bioorg Med Chem 2002;10:2353-2365.
20. Dunnington DJ, Hughes CM, Monaghan P, Rudland PS. Phenotypic instability of rat mammary tumor epithelial cells. J Natl Cancer Inst 1983;71:1227-1240. (Pubitemid 14182055)
21. El-Tanani MK, Campbell FC, Crowe P, et al. BRCA1 suppresses osteopontin-mediated breast cancer. J Biol Chem 2006;281: 26587-26601. (Pubitemid 44401868)
22. Moye VE, Barraclough R, West C, Rudland PS. Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines. Br J Cancer 2004;90:1796-1802. (Pubitemid 38725656)
23. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996;13:97-104. (Pubitemid 26248549)
24. Mason CK, McFarlane S, Johnston PG, et al. Agelastatin A: A novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther 2008;7:548-558.
25. Rosin-Arbesfeld R, Cliffe A, Brabletz T, Bienz M. Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription. EMBO J 2003;22:1101-1113. (Pubitemid 36313594)
26. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-1787. (Pubitemid 27136714)
27. Haddad JG, Hillman L, Rojanasathit S. Human serum binding capacity and affinity for 25-hydroxyergocalciferol and 25- hydroxycholecalciferol. J Clin Endocrinol Metab 1976;43: 86-91.
28. Wong G, Gupta R, Dixon KM, et al. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Biol 2004;89-90:567-570. (Pubitemid 38844350)
29. Jin D, El-Tanani M, Campbell FC. Identification of apolipo-protein D as a novel inhibitor of osteopontin-induced neoplastic transformation. Int J Oncol 2006;29:1591-1599.
30. El-Tanani M, Fernig DG, Barraclough R, Green C, Rudland P. Differential modulation of transcriptional activity of estrogen receptors by direct protein-protein interactions with the T cell factor family of transcription factors. J Biol Chem 2001;276: 41675-41682. (Pubitemid 37371060)
31. Staal FJ, Burgering BM, van de Wetering M, Clevers HC. Tcf- 1-mediated transcription in T lymphocytes: Differential role for glycogen synthase kinase-3 in fibroblasts and T cells. Int Immunol 1999;11:317-323.
32. Ridall AL, Daane EL, Dickinson DP, Butler WT. Characterization of the rat osteopontin gene. Evidence for two vitamin D response elements. Ann NY Acad Sci 1995;760:59-66.
33. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11: 1475-1489.
34. Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs - A brief overview. Mol Cell Biochem 2003; 253:247-254. (Pubitemid 37321732)
35. Ohta M, Okabe T, Ozawa K, Urabe A, Takaku F. 1 alpha,25- Dihydroxyvitamin D3 (calcitriol) stimulates proliferation of human circulating monocytes in vitro. FEBS Lett 1985;185: 9-13. (Pubitemid 15058177)
36. Itin PH, Pittelkow MR, Kumar R. Effects of vitamin D metabolites on proliferation and differentiation of cultured human epidermal keratinocytes grown in serum-free or defined culture medium. Endocrinology 1994;135:1793-1798. (Pubitemid 24363868)
37. Tokar EJ, Webber MM. Cholecalciferol (vitamin D3) inhibits growth and invasion by up-regulating nuclear receptors and 25-hydroxylase (CYP27A1) in human prostate cancer cells. Clin Exp Metastasis 2005;22:275-284. (Pubitemid 41298009)
38. Chang PL, Lee TF, Garretson K, Prince CW. Calcitriol enhancement of TPA-induced tumorigenic transformation is mediated through vitamin D receptor-dependent and -independent pathways. Clin Exp Metastasis 1997;15:580-592. (Pubitemid 27435739)
39. Reddy CD, Patti R, Guttapalli A, et al. Anticancer effects of the novel 1alpha, 25-dihydroxyvitamin D3 hybrid analog QW1624F2-2 in human neuroblastoma. J Cell Biochem 2006;97:198-206. (Pubitemid 43050191)
40. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-349.
41. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006;98:451-459.
42. Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007;99:1594-1602.
43. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502-1508. (Pubitemid 39202318)
44. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-696. (Pubitemid 43247139)
45. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED. Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study. Lancet 1989;2:1176-1178.
46. Tangrea J, Helzlsouer K, Pietinen P, et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 1997; 8:615-625. (Pubitemid 27330494)
47. Abnet CC, Chen W, Dawsey SM, et al. Serum 25(OH)-vitamin D concentration and risk of esophageal squamous dysplasia. Cancer Epidemiol Biomarkers Prev 2007;16:1889-1893.
48. Chen W, Dawsey SM, Qiao YL, et al. Prospective study of serum 25(OH)-vitamin D concentration and risk of oesophageal and gastric cancers. Br J Cancer 2007;97:123-128. (Pubitemid 47012092)
49. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 2004;108:104-108. (Pubitemid 37444451)
50. Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentration and prostate cancer risk: A nested case-control study. J Natl Cancer Inst 2008;100:796-804. (Pubitemid 351809669)
51. Stolzenberg-Solomon RZ, Vieth R, Azad A, et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006;66:10213-10219. (Pubitemid 44672077)
52. Li JJ, Kim RH, Zhang Q, Ogata Y, Sodek J. Characteristics of vitamin D3 receptor (VDR) binding to the vitamin D response element (VDRE) in rat bone sialoprotein gene promoter. Eur J Oral Sci 1998;106:408-417. (Pubitemid 128737257)
53. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin- Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-1790. (Pubitemid 27136715)
54. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006;17:463-474. (Pubitemid 44793123)
55. Vietor I, Kurzbauer R, Brosch G, Huber LA. TIS7 regulation of the beta-catenin/Tcf-4 target gene osteopontin (OPN) is histone deacetylase- dependent. J Biol Chem 2005;280: 39795-39801. (Pubitemid 41779112)
56. El-Tanani MK, Barraclough R, Wilkinson MC, Rudland PS. Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4. Oncogene 2001;20:1793-1797. (Pubitemid 32368025)
57. Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SW. The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem 2002;277:25313-25322. (Pubitemid 34951841)
58. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/ LEF-1-mediated transactivation. J Cell Sci 1999;112: 1237-1245. (Pubitemid 29218912)
59. Medici D, Hay ED, Olsen BR. Snail and slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3. Mol Biol Cell 2008;19:4875-4887.
60. Gumbiner BM. Cell adhesion: The molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-357.
61. Korita PV, Wakai T, Shirai Y, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol 2008;39:1777-1783.
62. Jaeger J, Koczan D, Thiesen HJ, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007;13:806-815. (Pubitemid 46340353)
63. Rohde F, Rimkus C, Friederichs J, et al. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer 2007;121: 1717-1723. (Pubitemid 47417288)
64. van der Wurff AA, Vermeulen SJ, van der Linden EP, Mareel MM, Bosman FT, Arends JW. Patterns of alpha- and beta-catenin and E-cadherin expression in colorectal adenomas and carcinomas. J Pathol 1997;182:325-330.
65. Pinsky PF, Schoen RE, Weissfeld JL, et al. The yield of surveillance colonoscopy by adenoma history and time to examination. Clin Gastroenterol Hepatol 2008.
66. Devoll RE, Li W, Woods KV, et al. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med 1999;28:97-101. (Pubitemid 29101029)
67. Santos-Garcia A, Abad-Hernandez MM, Fonseca-Sanchez E, et al. E-cadherin, laminin and collagen IV expression in the evolution from dysplasia to oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2006;11:E100-E105.
68. Wei WQ, Abnet CC, Lu N, et al. Risk factors for oesophageal squamous dysplasia in adult inhabitants of a high risk region of China. Gut 2005;54:759-763. (Pubitemid 40732088)